K. Drury

e13598 Background: The impact on cancer outcomes from the Covid-19 pandemic has yet to be determined. Concerns persist on screening, delays in diagnosis, treatment interruptions and outcomes of infection in the immunosuppressed. The need for agile working has been exemplified by establishment of Nightingale Hospitals, staff redeployment and sudden integration of virtual consultations into clinical working. With most cancer clinical trials halted, recruitment into COVID-19 research became essential and embedded into the everyday. Here we present how rapid implementation of COVID-19 randomised clinical trials within an NHS organisation during the pandemic was achieved. Methods: A COVID-19 senior facilitation committee was set up to provide oversight, maximise staff capacity and resource and prioritise studies. Specific strategies to maximise access and clinical trials recruitment for patients including children and those with solid tumours were designed. These included presence of a research nurse at clinical ward rounds and team meetings, the promotion of protocol and informed consent training to all including doctors in the acute settings and weekly research meetings to share-best practice. Reflecting on learnings from this time provide an opportunity to consider how we adjust working for our patients in the future. Results: The integration of research into the everyday working of clinical teams looking after patients with COVID-19 has become the norm. The provision of protocol and informed consent training for all levels of staff and the consideration of all patients for trials during clinical ward rounds and multi-disciplinary meetings, have ensured access to trials has become embedded. The integration of research nurses working, upskilling and prompting clinical colleagues has ensured equity of access and provided a research presence and focus during the busy clinical day. The adoption of cross-disciplinary working, sharing best practice and a culture of commitment and support to the trials ensures no patient is denied the opportunity to participate. Three RTCs opened over 7 weeks. At one site 1904 patients were screened for one of the randomised-controlled trials and over 18% of these patients (351) were recruited and 175 patients declined. Conclusions: The pandemic has had a devastating impact across the UK. However, a coordinated and collaborative multi-disciplinary approach has supported high recruitment and equity of access for patients into COVID-19 trials. Learnings from this work may lead to embedding clinical trials and access to translational research for cancer patients in the future as we recover from the full impact of the pandemic. COVID-19 research has demonstrated how increased recruitment accelerates access and implementation of new innovations and novel drug combinations.The full impact of improved access to cancer research in the future during COVID recovery is worthy of more research.

The TRIUMF Ultracold Advanced Neutron (TUCAN) collaboration has been developing a high-intensity ultracold neutron (UCN) source aimed at searching for the neutron electric dipole moment (EDM) with a sensitivity goal of $10^{-27}\ e{\rm cm}$. This article reports on recent progress in commissioning of the UCN source and in the development of the neutron EDM spectrometer. In its final configuration, the accelerator-driven super-thermal UCN source will enable a neutron EDM experiment with two orders of magnitude improved statistics compared to the current best experiment. Substantial progress in 2024 allowed the collaboration to operate the complete source system, with the exception of the liquid deuterium cold moderator, resulting in the first production of UCNs. The status of the EDM spectrometer is also presented, with emphasis on UCN handling components and magnetic subsystems relevant to field control, shielding, and magnetometry.

The TUCAN (TRIUMF UltraCold Advanced Neutron) Collaboration is completing a new ultracold neutron (UCN) source. The UCN source will deliver UCNs to a neutron electric dipole moment (EDM) experiment. The EDM experiment is projected to be capable of an uncertainty of 1 × 10−27 ecm, competitive with other planned projects, and a factor of ten more precise than the present world’s best. The TUCAN source is based on a UCN production volume of superfluid helium (He-II), held at 1 K, and coupled to a proton-driven spallation target. The production rate in the source is expected to be in excess of 107 UCN/s; since UCN losses can be small in superfluid helium, this should allow us to build up a large number of UCNs. The spallation-driven superfluid helium technology is the principal aspect making the TUCAN project unique. The superfluid production volume was recently cooled, for the first time, and successfully filled with superfluid helium. The design principles of the UCN source are described, along with some of the challenging cryogenic milestones that were recently passed.

We report the first results on ultracold neutron production from a new spallation-driven superfluid $^4$He (He-II) source at TRIUMF, which is being prepared for a new, precise measurement of the neutron electric dipole moment. A total of $(9.3 \pm 0.8)\times 10^{5}$ ultracold neutrons were observed at a proton beam current of \SI{37}{\uA}, when the target was irradiated for a period of \SI{60}{\s}. The results are in fair agreement with expectations based on a detailed simulation of neutron transport and ultracold neutron source cryogenics. There is some indication that the new source might not be as limited by the conduction of heat through the He-II as originally expected. The results indicate that the source is likely to make its ultimate production goals, once the liquid deuterium cold moderator system is completed, with the expectation that $5.7\times 10^7$~UCNs would be detected in the same experiment with full liquid levels. This would, for example, correspond to delivery of $1.4\times 10^6$~UCNs delivered to each of two nEDM measurement cells, and a statistical uncertainty of $1\times 10^{-27}~e$cm on the neutron EDM in 280 days of running.

We report the construction and commissioning of a new ultracold neutron (UCN) guide-coating facility at the University of Winnipeg. The facility employs pulsed laser deposition (PLD) to produce diamond-like carbon (DLC) coatings on cylindrical UCN guides up to 1 m in length with a 200 mm outer diameter. DLC is a promising material for UCN transport and storage due to its high real component of the optical potential, low neutron absorption cross section, and low depolarization probabilities. First coating attempts on a full length aluminum UCN guide and matching blank flange were successfully coated with a carbon film with density of 2.3 g/cm$^3$, corresponding to optical potentials of 200 neV, as measured by X-ray reflectometry (XRR). Coating thicknesses were measured to be 90 nm for the UCN guide and 180 nm for the flange with no evidence of delamination. The implementation of a plasma plume collimator and plasma feed back control via a time of flight in vacuum ion probe produced a film with an XRR measured density of 2.8 g/cm$^3$, corresponding to an optical potential of 240 neV. This 80 nm thick film had poor adhesion to the aluminum tube substrate. These results establish a baseline for the coating facility. Ongoing and future work focuses on improving the diamond content of films and adhesion through plasma plume collimation, TOF ion probe feed back, and pre/post treatment methods with the goal of providing high quality DLC UCN guides for the TUCAN experiment at TRIUMF.